Lexapro (Escitalopram) Dosing
For adults with major depressive disorder (MDD) or generalized anxiety disorder (GAD), start Lexapro at 10 mg once daily, which is also the recommended maintenance dose; the maximum dose is 20 mg once daily, though no additional benefit has been demonstrated at the higher dose. 1
Standard Adult Dosing
- Starting dose: 10 mg once daily
- Recommended therapeutic dose: 10 mg once daily
- Maximum dose: 20 mg once daily
- Administration: Once daily, morning or evening, with or without food 1
The FDA-approved dosing is straightforward: most patients achieve therapeutic benefit at 10 mg daily, and clinical trials have not demonstrated additional efficacy at 20 mg daily 1. This is consistent with guideline recommendations showing effective doses for adolescent depression at 10 mg daily with a maximum of 20 mg 2.
Special Populations
Elderly patients (≥65 years): The recommended dose is 10 mg once daily—do not exceed this dose 1. Older adults require lower dosing due to altered metabolism and increased sensitivity to adverse effects 3.
Hepatic impairment: Limit to 10 mg once daily due to decreased clearance and increased plasma concentrations 1.
Renal impairment: Use with caution in severe renal impairment, though specific dose adjustments are not established since escitalopram is extensively metabolized 1.
Pediatric Dosing
For adolescents aged 12-17 years with MDD or children/adolescents aged 7-17 years with GAD:
- Starting dose: 10 mg once daily
- Recommended dose: 10 mg once daily
- Maximum dose: 20 mg once daily 1
Important caveat: Evidence for escitalopram in pediatric MDD shows only small, borderline significant benefits (CDRS-R improvement of -2.46 points vs placebo), with high placebo response rates 4. Only fluoxetine has robust evidence for pediatric depression; escitalopram is FDA-approved for adolescents ≥12 years but should be reserved for cases where fluoxetine is unsuitable 2, 4.
Titration Strategy
Start low in sensitive patients: Because initial adverse effects can include anxiety or agitation, consider starting with a subtherapeutic "test" dose in anxious patients, then titrate to 10 mg 5.
Titration intervals: For shorter half-life SSRIs like escitalopram, increase doses at approximately 1-2 week intervals if needed, though most patients respond adequately to 10 mg 5.
Duration of adequate trial: Allow 4-6 weeks at therapeutic dose before assessing full response 2, 3.
Key Safety Considerations
QTc prolongation: Unlike citalopram (which has dose-dependent QTc prolongation and a 40 mg maximum), escitalopram shows minimal clinically meaningful QTc effects. Mean QTcF increase is only 1.3 ms at 10 mg and 1.7 ms at 20 mg 6. However, avoid in patients with long QT syndrome and use caution with other QTc-prolonging drugs 5.
Drug interactions: Escitalopram has the least effect on CYP450 enzymes compared to other SSRIs, resulting in lower propensity for drug interactions 5. Contraindicated with MAOIs due to serotonin syndrome risk 2.
Discontinuation: Taper gradually when stopping to minimize discontinuation syndrome (dizziness, paresthesias, anxiety, nausea) 2, 1. Escitalopram has less discontinuation syndrome than paroxetine or sertraline 5.
Monitoring
- Initial monitoring: Contact patient within first week to assess tolerability and adherence 2
- Ongoing: Monitor for suicidal ideation (especially in patients <25 years), serotonin syndrome, bleeding risk if combined with anticoagulants/NSAIDs, and sexual dysfunction 1
- Elderly patients: Monitor for hyponatremia and falls risk
Clinical Context
Escitalopram demonstrates efficacy comparable to other SSRIs with excellent tolerability—only nausea occurs in >10% of patients (≥5% above placebo) 7. Discontinuation due to adverse events is lower than paroxetine (6.6% vs 9.0%) or venlafaxine (6.1% vs 13.2%) 7. The 10 mg dose achieves therapeutic serotonin transporter occupancy (>80%) and corresponds to blood levels of 20-40 ng/mL 8.
Bottom line: Most patients should remain at 10 mg daily. Only increase to 20 mg if inadequate response after 4-6 weeks at 10 mg and good tolerability, recognizing that evidence for additional benefit is limited.